|
Duration of Treatment (y) |
Daily Dose |
Primary Disease Outcome |
Resultsb |
|
5 |
50 mg β-carotene |
Skin cancer |
No effect on occurrence of new nonmelanoma skin cancers |
|
5.25 |
15 mg β-carotene, 30 mg α-tocopherol, 50 mg selenium |
Cancer |
9% reduction in total mortality; 13% decrease in cancer mortality; 21% decrease in stomach cancer deaths; 10% decrease in cerebrovascular mortality (nonsignificant) |
|
6 |
50 mg α-tocopherol and/or 20 mg β-carotene |
Lung cancer |
50% increase in hemorrhagic stroke deaths among vitamin E group; 11% increase in ischemic heart disease deaths among β-carotene group; 18% increase in lung cancer among β-carotene group; no effect of vitamin E on lung cancer |
|
4 |
25 mg β-carotene, 1,000 mg vitamin C, 400 mg α-tocopherol |
Colorectal cancer |
No reduced incidence of adenomas |
|
4 |
30 mg β-carotene, 25,000 IU retinol (as retinyl palmitate) |
Lung cancer |
28% increase in lung cancer; 26% increase in CVDd (nonsignificant); 17% increase in total mortality among treatment group |
|
1.4 |
400 or 800 IU (268 or 537 mg) α-tocopherol |
CVD death or nonfatal MIf |
77% decrease in risk of subsequent nonfatal MI; no benefit on cardiovascular mortality |